| MeSH term | MeSH ID | Detail |
|---|---|---|
| Acute Kidney Injury | D058186 | 34 associated lipids |
| Burns | D002056 | 34 associated lipids |
| Anaphylaxis | D000707 | 35 associated lipids |
| Acne Vulgaris | D000152 | 35 associated lipids |
| Fever | D005334 | 35 associated lipids |
| Lung Diseases | D008171 | 37 associated lipids |
| Arthritis | D001168 | 41 associated lipids |
| Hypotension | D007022 | 41 associated lipids |
| Hypersensitivity, Delayed | D006968 | 43 associated lipids |
| Psoriasis | D011565 | 47 associated lipids |
Azithramycine
Azithramycine is a lipid of Polyketides (PK) class. Azithramycine is associated with abnormalities such as Respiratory Tract Infections, Pneumonia, Lower respiratory tract infection, Infection and Nonspecific urethritis. The involved functions are known as Lysis, Selection, Genetic, Mutation, Relapse and Adaptation. Azithramycine often locates in Blood, Respiratory System, Genitourinary system, Back and Chest. The associated genes with Azithramycine are Genes, rRNA, Genome, RPL22 gene, OPRM1 gene and tryptic soy broth. The related lipids are Liposomes, Phosphatidylserines, Promega, Lipopolysaccharides and Steroids. The related experimental models are Mouse Model, Knock-out and Tissue Model.
Cross Reference
Introduction
To understand associated biological information of Azithramycine, we collected biological information of abnormalities, associated pathways, cellular/molecular locations, biological functions, related genes/proteins, lipids and common seen animal/experimental models with organized paragraphs from literatures.
What diseases are associated with Azithramycine?
Azithramycine is suspected in Infection, Pneumonia, Trachoma, Respiratory Tract Infections, Gonorrhea, Infectious disease of lung and other diseases in descending order of the highest number of associated sentences.
Related references are mostly published in these journals:
- Antimicrob. Agents Chemother. (156)
- Clin. Infect. Dis. (64)
- J. Antimicrob. Chemother. (50)
- Others (435)
| Disease | Cross reference | Weighted score | Related literature |
|---|
Loading... please refresh the page if content is not showing up.
Possible diseases from mapped MeSH terms on references
We collected disease MeSH terms mapped to the references associated with Azithramycine
PubChem Associated disorders and diseases
What pathways are associated with Azithramycine
There are no associated biomedical information in the current reference collection.
PubChem Biomolecular Interactions and Pathways
Link to PubChem Biomolecular Interactions and PathwaysWhat cellular locations are associated with Azithramycine?
Visualization in cellular structure
Associated locations are in red color. Not associated locations are in black.
Related references are published most in these journals:
- Antimicrob. Agents Chemother. (66)
- J. Antimicrob. Chemother. (25)
- Clin. Infect. Dis. (13)
- Others (151)
| Location | Cross reference | Weighted score | Related literatures |
|---|
Loading... please refresh the page if content is not showing up.
What functions are associated with Azithramycine?
Related references are published most in these journals:
| Function | Cross reference | Weighted score | Related literatures |
|---|
What lipids are associated with Azithramycine?
Related references are published most in these journals:
| Lipid concept | Cross reference | Weighted score | Related literatures |
|---|
Loading... please refresh the page if content is not showing up.
What genes are associated with Azithramycine?
Related references are published most in these journals:
- Antimicrob. Agents Chemother. (44)
- J. Antimicrob. Chemother. (18)
- Clin. Infect. Dis. (10)
- Others (126)
| Gene | Cross reference | Weighted score | Related literatures |
|---|
What common seen animal models are associated with Azithramycine?
Mouse Model
Mouse Model are used in the study 'Azithromycin increases in vitro fibronectin production through interactions between macrophages and fibroblasts stimulated with Pseudomonas aeruginosa.' (Cory TJ et al., 2013), Mouse Model are used in the study 'Efficacy of azithromycin, clarithromycin and beta-lactam agents against experimentally induced bronchopneumonia caused by Haemophilus influenzae in mice.' (Miyazaki S et al., 2001), Mouse Model are used in the study 'Oral anti-pneumococcal activity and pharmacokinetic profiling of a novel peptide deformylase inhibitor.' (Gross M et al., 2004), Mouse Model are used in the study 'Inhibition of quorum sensing in Pseudomonas aeruginosa by azithromycin and its effectiveness in urinary tract infections.' (Bala A et al., 2011) and Mouse Model are used in the study 'Enhanced efficacy of single-dose versus multi-dose azithromycin regimens in preclinical infection models.' (Girard D et al., 2005).
Knock-out
Knock-out are used in the study 'Influence of rhlR and lasR on Polymyxin Pharmacodynamics in Pseudomonas aeruginosa and Implications for Quorum Sensing Inhibition with Azithromycin.' (Bulman ZP et al., 2017) and Knock-out are used in the study 'Azithromycin in Pseudomonas aeruginosa biofilms: bactericidal activity and selection of nfxB mutants.' (Mulet X et al., 2009).
Tissue Model
Tissue Model are used in the study 'Development of a population pharmacokinetic model characterizing the tissue distribution of azithromycin in healthy subjects.' (Zheng S et al., 2014).
Related references are published most in these journals:
| Model | Cross reference | Weighted score | Related literatures |
|---|
Loading... please refresh the page if content is not showing up.
NCBI Entrez Crosslinks
All references with Azithramycine
Download all related citations| Authors | Title | Published | Journal | PubMed Link |
|---|---|---|---|---|
| Suskova VS et al. | [Immuno-modulating properties of a macrolide antibiotic "Z-factor"]. | 2003 | Antibiot. Khimioter. | pmid:15002174 |
| Pisarev VV et al. | [Comparative study of azithromycin pharmacokinetics in healthy volunteers in open cross randomized procedure]. | 2003 | Antibiot. Khimioter. | pmid:15004973 |
| Bogdanov MB and Chernen'kaia TV | [Microbiological evaluation of antibiotics for empirical therapy of community-acquired infections of the lower respiratory tract]. | 2000 | Antibiot. Khimioter. | pmid:11212394 |
| Budanov SV | [Azithromycin (sumamed)--basic properties and therapy of community-acquired pneumonia]. | 2000 | Antibiot. Khimioter. | pmid:11212397 |
| Gomberg MA | [Combined treatment of persisting urogenital chlamydia infection with sumamed and interferon alfa]. | 2002 | Antibiot. Khimioter. | pmid:12365322 |
| Liu P et al. | Comparative pharmacokinetics of azithromycin in serum and white blood cells of healthy subjects receiving a single-dose extended-release regimen versus a 3-day immediate-release regimen. | 2007 | Antimicrob. Agents Chemother. | pmid:17060516 |
| Batt SL et al. | Impact of azithromycin administration for trachoma control on the carriage of antibiotic-resistant Streptococcus pneumoniae. | 2003 | Antimicrob. Agents Chemother. | pmid:12936971 |
| Henry DC et al. | Randomized double-blind study comparing 3- and 6-day regimens of azithromycin with a 10-day amoxicillin-clavulanate regimen for treatment of acute bacterial sinusitis. | 2003 | Antimicrob. Agents Chemother. | pmid:12936972 |
| Kohlhoff SA et al. | In vitro activity of AZD0914, a novel DNA gyrase inhibitor, against Chlamydia trachomatis and Chlamydia pneumoniae. | 2014 | Antimicrob. Agents Chemother. | pmid:25288086 |
| Phimda K et al. | Doxycycline versus azithromycin for treatment of leptospirosis and scrub typhus. | 2007 | Antimicrob. Agents Chemother. | pmid:17638700 |
| Bosnar M et al. | Cellular uptake and efflux of azithromycin, erythromycin, clarithromycin, telithromycin, and cethromycin. | 2005 | Antimicrob. Agents Chemother. | pmid:15917536 |
| Michot JM et al. | Active efflux of ciprofloxacin from J774 macrophages through an MRP-like transporter. | 2004 | Antimicrob. Agents Chemother. | pmid:15215125 |
| Hoberman A and Paradise JL | Study design questions in treatment of children with acute otitis media. | 2004 | Antimicrob. Agents Chemother. | pmid:15215151 |
| Singh S et al. | Antimycobacterial drugs modulate immunopathogenic matrix metalloproteinases in a cellular model of pulmonary tuberculosis. | 2014 | Antimicrob. Agents Chemother. | pmid:24890593 |
| Scorneaux B et al. | Effect of recombinant human gamma interferon on intracellular activities of antibiotics against Listeria monocytogenes in the human macrophage cell line THP-1. | 1996 | Antimicrob. Agents Chemother. | pmid:8723471 |
| Johnson MM et al. | Effect of carbon dioxide on testing of susceptibilities of respiratory tract pathogens to macrolide and azalide antimicrobial agents. | 1999 | Antimicrob. Agents Chemother. | pmid:10428903 |
| Credito KL et al. | Activity of telithromycin (HMR 3647) against anaerobic bacteria compared to those of eight other agents by time-kill methodology. | 1999 | Antimicrob. Agents Chemother. | pmid:10428930 |
| Unemo M et al. | First three Neisseria gonorrhoeae isolates with high-level resistance to azithromycin in Sweden: a threat to currently available dual-antimicrobial regimens for treatment of gonorrhea? | 2014 | Antimicrob. Agents Chemother. | pmid:24189248 |
| Li H et al. | Meta-analysis of the adverse effects of long-term azithromycin use in patients with chronic lung diseases. | 2014 | Antimicrob. Agents Chemother. | pmid:24189261 |
| Navarro G et al. | Image-based 384-well high-throughput screening method for the discovery of skyllamycins A to C as biofilm inhibitors and inducers of biofilm detachment in Pseudomonas aeruginosa. | 2014 | Antimicrob. Agents Chemother. | pmid:24295976 |
| Binet R et al. | Impact of azithromycin resistance mutations on the virulence and fitness of Chlamydia caviae in guinea pigs. | 2010 | Antimicrob. Agents Chemother. | pmid:20065052 |
| Dever LL et al. | Comparative in vitro activities of clarithromycin, azithromycin, and erythromycin against Borrelia burgdorferi. | 1993 | Antimicrob. Agents Chemother. | pmid:8215288 |
| Ohara T et al. | Effects of azithromycin on shiga toxin production by Escherichia coli and subsequent host inflammatory response. | 2002 | Antimicrob. Agents Chemother. | pmid:12384353 |
| Klemens SP and Cynamon MH | Intermittent azithromycin for treatment of Mycobacterium avium infection in beige mice. | 1994 | Antimicrob. Agents Chemother. | pmid:7986001 |
| Andersen SL et al. | Efficacy of azithromycin as a causal prophylactic agent against murine malaria. | 1994 | Antimicrob. Agents Chemother. | pmid:7986022 |
| Berry V et al. | Bacteriological efficacies of three macrolides compared with those of amoxicillin-clavulanate against Streptococcus pneumoniae and Haemophilus influenzae. | 1998 | Antimicrob. Agents Chemother. | pmid:9835514 |
| Niki Y et al. | In vitro and in vivo activities of azithromycin, a new azalide antibiotic, against chlamydia. | 1994 | Antimicrob. Agents Chemother. | pmid:7840560 |
| Biedenbach DJ et al. | Determination of CEM-101 activity tested against clinical isolates of Neisseria meningitidis from a worldwide collection. | 2010 | Antimicrob. Agents Chemother. | pmid:20625152 |
| Freeman CD et al. | Intracellular and extracellular penetration of azithromycin into inflammatory and noninflammatory blister fluid. | 1994 | Antimicrob. Agents Chemother. | pmid:7840585 |
| Piesman J et al. | Efficacy of an experimental azithromycin cream for prophylaxis of tick-transmitted lyme disease spirochete infection in a murine model. | 2014 | Antimicrob. Agents Chemother. | pmid:24165183 |
| Bastian S et al. | Assessment of clarithromycin susceptibility in strains belonging to the Mycobacterium abscessus group by erm(41) and rrl sequencing. | 2011 | Antimicrob. Agents Chemother. | pmid:21135185 |
| Chisholm SA et al. | High-level azithromycin resistance occurs in Neisseria gonorrhoeae as a result of a single point mutation in the 23S rRNA genes. | 2010 | Antimicrob. Agents Chemother. | pmid:20585125 |
| Fischer JH et al. | Influence of body weight, ethnicity, oral contraceptives, and pregnancy on the pharmacokinetics of azithromycin in women of childbearing age. | 2012 | Antimicrob. Agents Chemother. | pmid:22106226 |
| Jepras RI et al. | Rapid assessment of antibiotic effects on Escherichia coli by bis-(1,3-dibutylbarbituric acid) trimethine oxonol and flow cytometry. | 1997 | Antimicrob. Agents Chemother. | pmid:9303401 |
| Deshpande D et al. | Azithromycin Dose To Maximize Efficacy and Suppress Acquired Drug Resistance in Pulmonary Mycobacterium avium Disease. | 2016 | Antimicrob. Agents Chemother. | pmid:26810646 |
| Azoulay-Dupuis E et al. | Prophylactic and therapeutic activities of azithromycin in a mouse model of pneumococcal pneumonia. | 1991 | Antimicrob. Agents Chemother. | pmid:1656849 |
| Amacher DE et al. | Comparison of the effects of the new azalide antibiotic, azithromycin, and erythromycin estolate on rat liver cytochrome P-450. | 1991 | Antimicrob. Agents Chemother. | pmid:1656856 |
| Fass RJ | Erythromycin, clarithromycin, and azithromycin: use of frequency distribution curves, scattergrams, and regression analyses to compare in vitro activities and describe cross-resistance. | 1993 | Antimicrob. Agents Chemother. | pmid:8257127 |
| Gunell M et al. | In vitro activity of azithromycin against nontyphoidal Salmonella enterica. | 2010 | Antimicrob. Agents Chemother. | pmid:20498312 |
| Pfefferkorn ER and Borotz SE | Comparison of mutants of Toxoplasma gondii selected for resistance to azithromycin, spiramycin, or clindamycin. | 1994 | Antimicrob. Agents Chemother. | pmid:8141576 |
| Pene Dumitrescu T et al. | Development of a population pharmacokinetic model to describe azithromycin whole-blood and plasma concentrations over time in healthy subjects. | 2013 | Antimicrob. Agents Chemother. | pmid:23629714 |
| Amsden GW et al. | Pharmacokinetics in serum and leukocyte exposures of oral azithromycin, 1,500 milligrams, given over a 3- or 5-day period in healthy subjects. | 1999 | Antimicrob. Agents Chemother. | pmid:9869584 |
| Gelber RH et al. | Activities of various macrolide antibiotics against Mycobacterium leprae infection in mice. | 1991 | Antimicrob. Agents Chemother. | pmid:1648889 |
| Goswick SM and Brenner GM | Activities of azithromycin and amphotericin B against Naegleria fowleri in vitro and in a mouse model of primary amebic meningoencephalitis. | 2003 | Antimicrob. Agents Chemother. | pmid:12543653 |
| Hoffman HL et al. | Influence of macrolide susceptibility on efficacies of clarithromycin and azithromycin against Streptococcus pneumoniae in a murine lung infection model. | 2003 | Antimicrob. Agents Chemother. | pmid:12543686 |
| Breitschwerdt EB et al. | Efficacy of doxycycline, azithromycin, or trovafloxacin for treatment of experimental Rocky Mountain spotted fever in dogs. | 1999 | Antimicrob. Agents Chemother. | pmid:10103185 |
| Sjölund Karlsson M et al. | Outbreak of infections caused by Shigella sonnei with reduced susceptibility to azithromycin in the United States. | 2013 | Antimicrob. Agents Chemother. | pmid:23274665 |
| Hafner R et al. | Tolerance and pharmacokinetic interactions of rifabutin and azithromycin. | 2001 | Antimicrob. Agents Chemother. | pmid:11302832 |
| Donati M et al. | In vitro activities of several antimicrobial agents against recently isolated and genotyped Chlamydia trachomatis urogenital serovars D through K. | 2010 | Antimicrob. Agents Chemother. | pmid:20855744 |
| Patel KB et al. | Comparison of bronchopulmonary pharmacokinetics of clarithromycin and azithromycin. | 1996 | Antimicrob. Agents Chemother. | pmid:8891147 |